IMNM Q1 2023 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$2M-65.5% margin

Operating Income

-$4M-189.1% margin

Net Income

-$4M-180.6% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$24M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$48M

Total Liabilities

$34M

Stockholders' Equity

$14M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$2M	$0	—
Operating Income	-$4M	-$12M	+61.6%
Net Income	-$4M	-$12M	+63.4%